Depression Levels and Interferon Treatment in People with Multiple Sclerosis

Overview

Journal Int J MS Care

Date 2014 Jan 24

PMID 24453727

Citations 9

Authors

Sonya Kim

Frederick W Foley

Mary Ann Picone

June Halper

Vance Zemon

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is the most common cause of neurologic disease in young and middle-aged adults, and 75% of patients are female. Nearly one in two patients with MS will experience clinically significant depression-approximately three times the prevalence rate in the general population. This study used a cross-sectional approach to examine the link between depression levels and use of interferon medications among individuals with MS. Data were collected from 694 patients of the Multiple Sclerosis Comprehensive Care Center at Holy Name Medical Center in Teaneck, New Jersey. Analysis of variance was used to compare depression scores between patients taking and not taking interferons. Regression analyses with depression scores as the dependent variable were also conducted. The Beck Depression Inventory (BDI) was reduced to a set of dimensions by principal components analysis. Two components were identified, reflecting somatic and cognitive symptoms. The results showed no significant relationship between depression levels and interferon treatment. Significant associations were observed between depression and both age and disability status, with younger, more disabled patients tending to be more depressed.

Citing Articles

Relationship between Experiential Avoidance and Emotional Disturbances in Coping with Disease in Patients with Multiple Sclerosis.

Cuerda-Ballester M, Sancho-Cantus D, Martinez-Rubio D, Proano-Olmos B, Garcia-Pardo M, de la Rubia Orti J Behav Sci (Basel). 2024; 14(10).

PMID: 39457802 PMC: 11505163. DOI: 10.3390/bs14100930.

Quality of reporting health behaviors for multiple sclerosis (QuoRH-MS): A scoping review to inform intervention planning and improve consistency of reporting.

Probst Y, Kinnane E Brain Behav. 2024; 14(8):e3635.

PMID: 39148370 PMC: 11327400. DOI: 10.1002/brb3.3635.

Combining inflammatory miRNA molecules as diagnostic biomarkers for depression: a clinical study.

Bras J, Pinto S, von Doellinger O, Prata J, Coelho R, Barbosa M Front Psychiatry. 2023; 14:1227618.

PMID: 37575572 PMC: 10413105. DOI: 10.3389/fpsyt.2023.1227618.

Determining Prevalence of Depression and Covariates of Depression in a Cohort of Multiple Sclerosis Patients.

Tardo L, McCreary M, Majeed H, Greenberg B J Cent Nerv Syst Dis. 2022; 14:11795735221098143.

PMID: 35558003 PMC: 9087231. DOI: 10.1177/11795735221098143.

Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).

Cohan S, Hendin B, Reder A, Smoot K, Avila R, Mendoza J CNS Drugs. 2021; 35(7):743-767.

PMID: 34228301 PMC: 8258741. DOI: 10.1007/s40263-021-00822-z.

References

Arnaud P . [The interferons: pharmacology, mechanism of action, tolerance and side effects]. Rev Med Interne. 2002; 23 Suppl 4:449s-458s. DOI: 10.1016/s0248-8663(02)00659-8. View

. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993; 43(4):655-61. DOI: 10.1212/wnl.43.4.655. View

Goeb J, Even C, Nicolas G, Gohier B, Dubas F, Garre J . Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry. 2006; 21(3):186-93. DOI: 10.1016/j.eurpsy.2005.09.013. View

Slater R . Criteria and uses of the Minimal Record of Disability in multiple sclerosis. Acta Neurol Scand Suppl. 1984; 101:16-20. DOI: 10.1111/j.1600-0404.1984.tb02545.x. View

Feinstein A, OConnor P, Feinstein K . Multiple sclerosis, interferon beta-1b and depression A prospective investigation. J Neurol. 2002; 249(7):815-20. DOI: 10.1007/s00415-002-0725-0. View

McGlone J, Santor D . Somatic complaints disproportionately contribute to Beck Depression Inventory estimates of depression severity in individuals with multiple chemical sensitivity. J Occup Environ Med. 1998; 40(10):862-9. DOI: 10.1097/00043764-199810000-00005. View

Wallin M, Wilken J, Turner A, Williams R, Kane R . Depression and multiple sclerosis: Review of a lethal combination. J Rehabil Res Dev. 2006; 43(1):45-62. DOI: 10.1682/jrrd.2004.09.0117. View

Mohr D, Likosky W, Dwyer P, Van Der Wende J, Boudewyn A, Goodkin D . Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol. 1999; 56(10):1263-5. DOI: 10.1001/archneur.56.10.1263. View

Pittock S, Mayr W, McClelland R, Jorgensen N, Weigand S, Noseworthy J . Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology. 2004; 62(4):601-6. DOI: 10.1212/wnl.62.4.601. View

10.

Gold S, Irwin M . Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Neurol Clin. 2006; 24(3):507-19. DOI: 10.1016/j.ncl.2006.03.007. View

11.

Patten S, Williams J, Metz L . Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler. 2007; 14(3):406-11. DOI: 10.1177/1352458507082942. View

12.

Porcel J, Rio J, Sanchez-Betancourt A, Arevalo M, Tintore M, Tellez N . Long-term emotional state of multiple sclerosis patients treated with interferon beta. Mult Scler. 2007; 12(6):802-7. DOI: 10.1177/1352458506070748. View

13.

Dunn A, Swiergiel A, de Beaurepaire R . Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev. 2005; 29(4-5):891-909. DOI: 10.1016/j.neubiorev.2005.03.023. View

14.

Lee T, Tsai S, Yang C, Hwang J . Clinical and phenomenological comparisons of delusional and non-delusional major depression in the Chinese elderly. Int J Geriatr Psychiatry. 2003; 18(6):486-90. DOI: 10.1002/gps.870. View

15.

. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005; 11(3):328-37. DOI: 10.1191/1352458505ms1162oa. View

16.

Roose S, Glassman A, Walsh B, Woodring S . Depression, delusions, and suicide. Am J Psychiatry. 1983; 140(9):1159-62. DOI: 10.1176/ajp.140.9.1159. View

17.

Zivadinov R, Zorzon M, Tommasi M, Nasuelli D, Bernardi M, Monti-Bragadin L . A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci. 2003; 216(1):113-8. DOI: 10.1016/s0022-510x(03)00225-9. View

18.

Neilley L, Goodin D, Goodkin D, Hauser S . Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology. 1996; 46(2):552-4. DOI: 10.1212/wnl.46.2.552. View

19.

Galeazzi G, Ferrari S, Giaroli G, Mackinnon A, Merelli E, Motti L . Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci. 2005; 26(4):255-62. DOI: 10.1007/s10072-005-0468-8. View

20.

Minor T, Huang Q, Witt A . Cytokine-purine interactions in traumatic stress, behavioral depression, and sickness. CNS Neurol Disord Drug Targets. 2006; 5(5):547-60. DOI: 10.2174/187152706778559282. View